Renaissance Pharma is a clinical-stage pharmaceutical company focused on developing immunotherapy treatments for high-risk neuroblastoma in pediatric patients. The company aims to enhance therapeutic options for rare pediatric diseases, addressing the critical need for effective treatments in this underserved patient population.
Funding
Funding not disclosed
Founders
Product
Problem
High-risk neuroblastoma, a rare pediatric cancer, lacks sufficient effective treatment options, resulting in a critical unmet need for improved therapeutic interventions. Current standard treatments often fail to prevent disease recurrence and can have significant long-term side effects in young patients.
Solution
Renaissance Pharma is developing a novel immunotherapy, Hu14.18, to enhance outcomes for children with newly diagnosed high-risk neuroblastoma. This humanized anti-GD2 monoclonal antibody is designed to be incorporated into standard induction chemotherapy regimens. Clinical trial data has demonstrated promising results, showing improved event-free and overall survival rates compared to historical controls. The company aims to provide a life-enhancing therapy that addresses the limitations of existing treatments and reduces the risk of relapse in this vulnerable patient population.
Target Audience
The primary target audience includes pediatric oncologists and hematologists specializing in neuroblastoma treatment, as well as hospitals and cancer centers focused on pediatric oncology.
Features
- Hu14.18: A humanized anti-GD2 monoclonal antibody targeting neuroblastoma cells.
- Designed for integration with standard induction chemotherapy protocols.
- Demonstrated a 73.7% 3-year event-free survival (EFS) rate in a Phase II trial.
- Showed an 86.0% 3-year overall survival (OS) rate in the same Phase II trial.